GVHD,Acute, Stem Cell Transplant Complications
Conditions
Keywords
acute graft-versus-host disease, Ruxolitinib, first line therapy
Brief summary
The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for grade II acute GVHD (graft-versus-host disease )
Detailed description
Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression as first line therapy. Many patients with grade II acute GVHD do not respond to primary therapy, high-dose systemic corticosteroids; therefore, survival for those patients remains particularly poor. Here we determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the Treatment of grade II acute GVHD.
Interventions
DRUGRuxolitinib
Participants began oral administration of ruxolitinib at 5 mg QD;Methylprednisolone: 0.5mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
DRUGCorticosteroids
Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
Sponsors
Daihong Liu
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Drug:Ruxolitinib, Corticosteroids
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diagnosed with hematological diseases. 2. Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies. 3. New onset of grade II acute GVHD or intermediate or high risk aGVHD (based on modified GVHD Glucksberg criteria) within 100 days post-transplantation.
Exclusion criteria
1. Recipients of second allogeneic stem cell transplant. 2. Acute GVHD induced by donor lymphocyte infusion, interferon. 3. Received first line aGVHD treatment before enrollment. 4. Overlap GVHD syndrome. 5. Pregnant or breast-feeding women. 6. Pregnant or breast-feeding women. 7. Serum creatinine \> 2.0 mg/dL or creatinine clearance \< 40 mL/min measured or calculated by Cockroft-Gault equation. 8. Uncontrolled infection. 9. Human immunodeficiency virus infection. 10. Active hepatitis b virus, hepatitis C virus infection and need antivirus treatment. 11. Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed, or graft rejection. 12. Allergic history to Janus kinase inhibitors. 13. Severe organ dysfunction unrelated to underlying GVHD, including: (1)Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction). (2)Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy. (3)Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen. 14.Received Janus kinase inhibitor therapy after allo-HSCT for any indication. 15.Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) at Day 28 | Day 28 after treatment | Defined as the proportion of participants demonstrating a complete response (CR), or partial response (PR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of response | Day 90 after treatment | Defined as the time from first response until GVHD progression or death, when all participants who are still on study complete the Day 90 visit. |
| Nonrelapse mortality (NRM) | 1 year after treatment | NRM was defined as death from any cause without relapse. Cumulative incidence of NRM was analyzed in a competing risk framework using Gray's method. |
| Cumulative incidence of relapse (CIR) | 1 year after treatment | Defined as the proportion of participants whose underlying malignancy relapsed.Relapse was defined as hematologic recurrence of malignancies after transplantation. Cumulative incidence of relapse was analyzed in a competing risk framework using Gray's method. |
| Disease-free survival (DFS) | 1 year after treatment | Defined as the time from day +1 to the earliest date that a participant died, had a relapse/progression of the underlying malignancy, required additional therapy for aGVHD, or demonstrated signs or symptoms of chronic graft-versus-host disease (cGVHD).DFS will be evaluated in an intent-to-treat analysis by Kaplan Meier estimate and Log Rank test. |
| Six-month duration of response | Six-month after treatment | Defined as the time from first response until graft-versus-host disease (GVHD) progression or death. Six-month duration of response will be assessed when all participants who are still on study complete the Day 180 visit. |
| GVHD-free and relapse-free survival (GRFS) | 1 year after treatment | Defined as a composite endpoint of death from any cause, disease relapse, grade Ⅲ-Ⅳ acute GVHD, or chronic GVHD requiring systemic immunosuppression therapy. |
| Recurrence of aGVHD | 1 year after treatment | Defined as the proportion of participants whose aGVHD relapsed.Relapse was defined as recurrence of new GVHD related symptoms after complete remission of aGVHD. Cumulative incidence of recurrence of aGVHD was analyzed in a competing risk framework using Gray's method. |
| Failure-free survival | 1 year after treatment | Failure-free survival (FFS) refers to the time from day +1 to disease relapse or progression, non-relapse mortality, or the addition of new therapy for aGVHD. |
| Overall survival (OS) | 1 year after treatment | Defined as survival from day +1 until death or last follow-up. OS will be evaluated in an intent-to-treat analysis by Kaplan Meier estimate and Log Rank test. Survival will be calculated from the date of randomization. |
Countries
China
Contacts
Primary ContactLiping Dou, M.D., Ph.D.
Outcome results
None listed